Generation and Production of Engineered Antibodies
Overview
Molecular Biology
Authors
Affiliations
Various forms of recombinant monoclonal antibodies are being used increasingly, mainly for therapeutic purposes. This review specifically focuses on what is now called antibody engineering, and discusses the generation of chimeric, humanized, and fully human recombinant antibodies, immunoglobulin fragments, and artificial antigen-binding molecules. Since the production of recombinant antibodies is a limiting factor in their availability, and a shortage is expected in the future, different expression systems for recombinant antibodies and transgenic organisms as bioreactors are also discussed, along with their advantages and drawbacks.
Directing evolution of novel ligands by mRNA display.
Kamalinia G, Grindel B, Takahashi T, Millward S, Roberts R Chem Soc Rev. 2021; 50(16):9055-9103.
PMID: 34165126 PMC: 8725378. DOI: 10.1039/d1cs00160d.
The reduced form of the antibody CH2 domain.
Xi Z, Liu X, Lin R, Persons J, Ilina T, Li W Protein Sci. 2021; 30(9):1895-1903.
PMID: 34107549 PMC: 8376410. DOI: 10.1002/pro.4142.
Kazuma S, Cavalcante M, Telles A, Maranhao A, Abdalla D MAbs. 2013; 5(5):763-75.
PMID: 23924793 PMC: 3851228. DOI: 10.4161/mabs.25859.
Hasegawa H Int J Cell Biol. 2013; 2013:604867.
PMID: 23533417 PMC: 3603282. DOI: 10.1155/2013/604867.
Kim H, McCoy M, Majkova Z, Dechant J, Gee S, Tabares-da Rosa S Anal Chem. 2011; 84(2):1165-71.
PMID: 22148739 PMC: 3264785. DOI: 10.1021/ac2030255.